Literature DB >> 34907725

Moonlight human ribosomal protein L13a downregulation is associated with p53 and HER2/neu expression in breast cancer.

Ghader Molavi1,2, Nasser Samadi1,2,3, Shahriar Hashemzadeh4,5, Monireh Halimi6, Elaheh Zadeh Hosseingholi7.   

Abstract

Breast cancer is the most common malignancy among females worldwide. Recent studies have shown extra-ribosomal roles of the moonlight ribosomal proteins in the development of human cancers. Accurate quantification of the gene expression level is based on the selection of the reference genes whose expression is independent of cancer properties and patient's characteristics. The aim of this study was the evaluation of the expression level of a previously proposed ribosomal protein as moonlight, L13a (RPL13A), in breast cancer samples and their adjacent tissues. Its association with genes of known roles in developing cancers was also investigated. Traditionally used housekeeping genes were selected and their expression was analyzed in 80 surgically excised breast tissue specimens (40 tumors and 40 tumor-adjacent tissues) by applying three software tools including GeNorm, NormFinder, and BestKeeper to select the most stable reference genes. Then, mRNA expression levels of RPL13A and p53 were evaluated. Additionally, protein expression levels of RPL13A were measured. It was demonstrated that PUM1 and ACTB are the most reliable reference genes and RPL13A is the least stable gene. There was a positive correlation between RPL13A and p53 mRNA expression levels in all the tumor samples. Moreover, significant downregulation of RPL13A expression levels was revealed in HER2+ tumor samples compared to HER2- ones. There was also a marked decrease in p53 mRNA expression levels in HER2+ tumor subtypes. Our results suggest that there is a probable relationship between RPL13A decreased expression with p53 and HER2/neu expression in the breast cancer.

Entities:  

Keywords:  Breast neoplasms; ErbB receptors; Ribosomal proteins; Tumor suppressor protein p53

Mesh:

Substances:

Year:  2020        PMID: 34907725     DOI: 10.32725/jab.2020.008

Source DB:  PubMed          Journal:  J Appl Biomed        ISSN: 1214-021X            Impact factor:   1.797


  39 in total

1.  Evaluation and identification of reliable reference genes for pharmacogenomics, toxicogenomics, and small RNA expression analysis.

Authors:  Dongliang Chen; Xiaoping Pan; Peng Xiao; Mary A Farwell; Baohong Zhang
Journal:  J Cell Physiol       Date:  2011-10       Impact factor: 6.384

2.  Proteomic characterization of Her2/neu-overexpressing breast cancer cells.

Authors:  Hexin Chen; Genaro Pimienta; Yiben Gu; Xu Sun; Jianjun Hu; Min-Sik Kim; Raghothama Chaerkady; Marjan Gucek; Robert N Cole; Saraswati Sukumar; Akhilesh Pandey
Journal:  Proteomics       Date:  2010-11       Impact factor: 3.984

3.  Human ribosomal protein L13a is dispensable for canonical ribosome function but indispensable for efficient rRNA methylation.

Authors:  Sujan Chaudhuri; Keyur Vyas; Purvi Kapasi; Anton A Komar; Jonathan D Dinman; Sailen Barik; Barsanjit Mazumder
Journal:  RNA       Date:  2007-10-05       Impact factor: 4.942

4.  Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets.

Authors:  Claus Lindbjerg Andersen; Jens Ledet Jensen; Torben Falck Ørntoft
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

5.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 6.  The other lives of ribosomal proteins.

Authors:  Rital B Bhavsar; Leah N Makley; Panagiotis A Tsonis
Journal:  Hum Genomics       Date:  2010-06       Impact factor: 4.639

Review 7.  Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential.

Authors:  Claudia Cava; Gloria Bertoli; Isabella Castiglioni
Journal:  BMC Syst Biol       Date:  2015-09-21

8.  ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function.

Authors:  Igor Bado; Eric Pham; Benjamin Soibam; Fotis Nikolos; Jan-Åke Gustafsson; Christoforos Thomas
Journal:  Oncotarget       Date:  2018-04-27

Review 9.  HDL and LDL: Potential New Players in Breast Cancer Development.

Authors:  Lídia Cedó; Srinivasa T Reddy; Eugènia Mato; Francisco Blanco-Vaca; Joan Carles Escolà-Gil
Journal:  J Clin Med       Date:  2019-06-14       Impact factor: 4.241

Review 10.  Cellular differences in protein synthesis regulate tissue homeostasis.

Authors:  Michael Buszczak; Robert A J Signer; Sean J Morrison
Journal:  Cell       Date:  2014-10-09       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.